RBD-specific single-chain antibody protects against acute lung injury in mice

Shanshan Peng; Syed Husnain Raza Shah; Shengsheng Mei; Eu Gene Vong; Yisheng Sun; Jinbiao Zhan

doi:10.1016/j.intimp.2023.111020

RBD-specific single-chain antibody protects against acute lung injury in mice

Int Immunopharmacol. 2023 Nov;124(Pt B):111020. doi: 10.1016/j.intimp.2023.111020. Epub 2023 Oct 7.

Authors

Shanshan Peng¹, Syed Husnain Raza Shah¹, Shengsheng Mei¹, Eu Gene Vong¹, Yisheng Sun², Jinbiao Zhan³

Affiliations

¹ Department of Biochemistry and Cancer Institute of the Second Affiliated Hospital (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education), School of Medicine, Zhejiang University, Hangzhou 310056, China.
² Key Lab of Vaccine, Prevention and Control of Infectious Disease of Zhejiang Province, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou 310015, China.
³ Department of Biochemistry and Cancer Institute of the Second Affiliated Hospital (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education), School of Medicine, Zhejiang University, Hangzhou 310056, China. Electronic address: jzhan2k@zju.edu.cn.

PMID: 37812969
DOI: 10.1016/j.intimp.2023.111020

Abstract

As SARS-CoV-2 variants continue spreading globally, the discovery of broad spectrum therapeutically active antibodies with retaining good protective activity is a global priority. It was reported that infection with SARS-CoV-2 could cause acute lung injury (ALI) in clinical investigations. Therefore, we discovered that anti-RBD scFv is effective against SARS-CoV-2-induced ALI. To begin, we utilized the receptor binding domain (RBD) of spike glycoprotein as a target to produce single-chain antibodies (scFvs) through an intensive phage display technology. The binding affinity and inhibitory effect of the scFvs were evaluated via ELISA and flow cytometry. Moreover, anti-RBD scFv No.35 significantly prevented ALI caused by LPS and SARS-CoV-2 spike RBD protein in mouse model. Thus, the anti-RBD scFv will aid the development of potential antibody treatments and reduce the inflammatory response of SARS-CoV-2.

Keywords: Acute lung injury; COVID-19; Phage display; Receptor binding domains; SARS-CoV-2; scFv.

MeSH terms

Acute Lung Injury* / drug therapy
Animals
Antibodies, Neutralizing / therapeutic use
Antibodies, Viral / therapeutic use
Mice
Protein Binding
Single-Chain Antibodies* / therapeutic use

Substances

Antibodies, Viral
Single-Chain Antibodies
Antibodies, Neutralizing